In all cancer samples, ASB18-AS1 expression had an overall significant difference among the four immune subtypes [C1 (wound healing), C2 (IFN-γ dominant), C3 (inflammatory), C4 (lymphocyte deplete)] (p <0.001). This evidence concerns the gene IFNG and cancer.